Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice

Cancer Research

Volumn 68, Issue 9, 2008, Pages 3540-3548

  Lee, Chung Wei ^a,b   Rickman, Barry ^a   Rogers, Arlin B ^a   Ge, Zhongming ^a   Wang, Timothy C ^c   Fox, James G ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; GAMMA INTERFERON; GASTRIN; INDUCIBLE NITRIC OXIDE SYNTHASE; METRONIDAZOLE; OMEPRAZOLE; PROTEIN REG 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIULCER AGENT; LITHOSTATHINE; NOS2 PROTEIN, MOUSE; REG1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DYSPLASIA; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HYPERGASTRINEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; ANIMAL; C57BL MOUSE; CARCINOMA IN SITU; DISEASE COURSE; DRUG EFFECT; METABOLISM; MICROBIOLOGY; PATHOLOGY; PRECANCER; STOMACH MUCOSA; STOMACH TUMOR; STOMACH ULCER;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; CARCINOMA IN SITU; CELL PROLIFERATION; CLARITHROMYCIN; DISEASE PROGRESSION; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; INTERFERON TYPE II; LITHOSTATHINE; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II; OMEPRAZOLE; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS; STOMACH ULCER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44849136207     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6786     Document Type: Article

References (44)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-5.
2. International Agency for Research on Cancer. Schistosomes, liver flukes, and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
3. Fox JG, Wang TC. Helicobacter pylori - not a good bug after all! N Engl J Med 2001;345:829-32.
4. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48:3554-60.
5. Ley C, Mohar A, Guarner J, et al. Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 2004;13:4-10.
6. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-83.
7. Ito M, Haruma K, Kamada T, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002;16:1449-56.
8. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8.
9. Mera R, Fontham ET, Bravo LE, et al. Long-term follow-up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536-40.
10. Nyren O, McLaughlin JK, Gridley G, et al. Cancer risk after hip replacement with metal implants: a population-based cohort study in Sweden. J Natl Cancer Inst 1995;87:28-33.
11. Akre K, Signorello LB, Engstrand L, et al. Risk for gastric cancer after antibiotic prophylaxis in patients undergoing hip replacement. Cancer Res 2000;60:6376-80.
12. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.
13. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-9.
14. Cao X, Tsukamoto T, Nozaki K, et al. Eradication of Helicobacter pylori induces apoptosis and inhibits proliferation of heterotopic proliferative glands in infected Mongolian gerbils. Cancer Sci 2004;95:872-7.
15. Cai X, Carlson J, Stoicov C, Li H, Wang TC, Houghton J. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. Gastroenterology 2005;128:1937-52.
16. Fox JG, Wang TC, Rogers AB, et al. Host and microbial constituents influence Helicobacter pylori-induced cancer in a murine model of hypergastrinemia. Gastroenterology 2003;124:1879-90.
17. Konda Y, Kamimura H, Yokota H, Hayashi N, Sugano K, Takeuchi T. Gastrin stimulates the growth of gastric pit with less-differentiated features. Am J Physiol 1999;277:G773-84.
18. Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000;118:36-47.
19. Fox JG, Rogers AB, Ihrig M, et al. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer Res 2003;63:942-50.
20. Wang TC, Koh TJ, Varro A, et al. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Invest 1996;98:1918-29.
21. Ohtani M, Garcia A, Rogers AB, et al. Protective role of 17β-estradiol against the development of Helicobacter pylori-induced gastric cancer in INS-GAS mice. Carcinogenesis 2007;28:2597-604.
22. Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997;112:1386-97.
23. -/- mice, but only wild-type regulatory T cells suppress Helicobacter pylori gastritis. Infect Immun 2007;75:2699-707.
24. van Zanten SJ, Kolesnikow T, Leung V, O'Rourke JL, Lee A. Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model. Antimicrob Agents Chemother 2003;47:2249-55.
25. Rogers AB, Taylor NS, Whary MT, Stefanich ED, Wang TC, Fox JG. Helicobacter pylori but not high salt induces gastric intraepithelial neoplasia in B6129 mice. Cancer Res 2005;65:10709-15.
26. Boivin GP, Washington K, Yang K, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003;124:762-77.
27. Maurer KJ, Rogers AB, Ge Z, Wiese AJ, Carey MC, Fox JG. Helicobacter pylori and cholesterol gallstone formation in C57L/J mice: a prospective study. Am J Physiol Gastrointest Liver Physiol 2006;290:G175-82.
28. Ihrig M, Whary MT, Dangler CA, Fox JG. Gastric Helicobacter infection induces a Th2 phenotype but does not elevate serum cholesterol in mice lacking inducible nitric oxide synthase. Infect Immun 2005;73:1664-70.
29. Fukui H, Kinoshita Y, Maekawa T, et al. Regenerating gene protein may mediate gastric mucosal proliferation induced by hypergastrinemia in rats. Gastroenterology 1998;115:1483-93.
30. Takaishi S, Cui G, Frederick DM, et al. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology 2005;128:1965-83.
31. Li Q, Karam SM, Gordon JI. Diphtheria toxin-mediated ablation of parietal cells in the stomach of transgenic mice. J Biol Chem 1996;271:3671-6.
32. Kang W, Rathinavelu S, Samuelson LC, Merchant JL. Interferon γ induction of gastric mucous neck cell hypertrophy. Lab Invest 2005;85:702-15.
33. Fox JG, Rogers AB, Whary MT, et al. Accelerated progression of gastritis to dysplasia in the pyloric antrum of TFF2/C57BL6 x Sv129 Helicobacter pylori-infected mice. Am J Pathol 2007;171:1520-8.
34. Biasco G, Paganelli GM, Miglioli M, Barbara L. Cell proliferation biomarkers in the gastrointestinal tract. J Cell Biochem 1992;16G:73-8.
35. Biasco G, Paganelli GM, Santucci R, Miglioli M, Barbara L. Cell proliferation kinetics as a marker of gastric cancer risk. Ital J Gastroenterol 1991;23:24-8.
36. Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A 2006;103:732-7.
37. Sarma-Rupavtarm RB, Ge Z, Schauer DB, Fox JG, Polz MF. Spatial distribution and stability of the eight microbial species of the altered Schaedler flora in the mouse gastrointestinal tract. Appl Environ Microbiol 2004;70:2791-800.
38. Zavros Y, Rieder G, Ferguson A, Merchant JL. Gastritis and hypergastrinemia due to Acinetobacter lwoffii in mice. Infect Immun 2002;70:2630-9.
39. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest 2007;117:60-9.
40. Adamsson I, Nord CE, Lundquist P, Sjostedt S, Edlund C. Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother 1999;44:629-40.
41. Sung J, Lin S, Ching J, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7-14.
42. International Agency for Research on Cancer. Cancer incidence in five continents. In: Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Vol. 7. Lyon: IARC Sci Publ; 1997.
43. Mera R, Fontham ET, Bravo LE, et al. Re: Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:1426.
44. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.